BridgeMD
Continuous versus intermittent intravenous furosemide treatment in patients hospitalised with acute heart failure
EU CTIS ID: 2025-523589-26-00
What this study is testing
To determine if there is a difference in the diuretic treatment effect in acute heart failure between intravenous administration of furosemide by either continuous infusion preceded by a loading dose or bolus injections three times a day.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Clinical diagnosis of acute heart failure with volume overload
- ≥ 1 sign of volume overload
- Anticipated intravenous furosemide ≥ 3 days
- Age ≥ 18 years
You likely can't join if
- Shock
- Patient requiring treatment with inotropes or vasopressors
- Current or planned use of renal replacement therapy or ultrafiltration
- Patient with a renal transplant
- Patients who are pregnant or breastfeeding
- Severe hypokalaemia (<2.5 mmol/L) or severe hyponatremia (<125 mmol/L)
See the full eligibility criteria
- Clinical diagnosis of acute heart failure with volume overload
- ≥ 1 sign of volume overload
- Anticipated intravenous furosemide ≥ 3 days
- Age ≥ 18 years
- Shock
- Patient requiring treatment with inotropes or vasopressors
- Current or planned use of renal replacement therapy or ultrafiltration
- Patient with a renal transplant
- Patients who are pregnant or breastfeeding
- Severe hypokalaemia (<2.5 mmol/L) or severe hyponatremia (<125 mmol/L)
- Allergy to furosemide and its components
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.